DIC invests in US-based biotech startup
Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
The project is part of a three-year-long partnership between Honeywell and Americares to strengthen the health infrastructure in rural Maharashtra, Uttarakhand and Haryana
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Medical Device Policy is a progressive step in propelling the country towards Atmanirbharta in the heavily import dependent Medical Device Sector
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Subscribe To Our Newsletter & Stay Updated